Integrating and Simplifying Evidence to Optimize Cardiorenal Guideline-Directed Therapies.

Chronic kidney disease (CKD) prevalence is rising worldwide and is projected to become the fifth leading cause of death globally by 2040. The high proportion of undiagnosed early-staged CKD and delayed diagnosis is of significant concern. The access to diagnosis and treatment is also limited in low-resource settings. The majority of individuals with kidney disease succumb to cardiovascular disease complications. Furthermore, heart failure and CKD are closely interconnected, with each condition significantly increasing the risk of developing the other. They share common risk factors, such as high blood pressure and diabetes, and their coexistence worsens prognosis and raises mortality rates. The bidirectional relationship between the heart and kidneys becomes even more complex and challenging in the context of cardiorenal syndrome. Emerging medications, such as sodium-glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists, have shown remarkable efficacy in slowing the progression of kidney disease, surpassing the benefits of traditional treatments. This article summarizes the evidence on the early detection of CKD and real-world opportunities to slow the progression of CKD by optimizing cardiorenal guideline-directed medical therapy.